CONTEXT: Studies of depressed psychiatric patients have shown that antidepressant efficacy can be increased by augmentation with omega-3 fatty acids. OBJECTIVE: To determine whether omega-3 improves the response to sertraline in patients with major depression and coronary heart disease (CHD). DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial. Between May 2005 and December 2008, 122 patients in St Louis, Missouri, with major depression and CHD were randomized. INTERVENTIONS: After a 2-week run-in period, all patients were given 50 mg/d of sertraline and randomized in double-blind fashion to receive 2 g/d of omega-3 acid ethyl esters (930 mg of eicosapentaenoic acid [EPA] and 750 mg of docosahexaenoic acid [DHA]) (n=62) or to corn oil placebo capsules (n=60) for 10 weeks. MAIN OUTCOME MEASURES: Scores on the Beck Depression Inventory (BDI-II) and the Hamilton Rating Scale for Depression (HAM-D). RESULTS: Adherence to the medication regimen was 97% or more in both groups for both medications. There were no differences in weekly BDI-II scores (treatment x time interaction = 0.02; 95% confidence interval [CI], -0.33 to 0.36; t(112) = 0.11; P = .91), pre-post BDI-II scores (placebo, 14.8 vs omega-3, 16.1; 95% difference-in-means CI, -4.5 to 2.0; t(116) = -0.77; P = .44), or HAM-D scores (placebo, 9.4 vs omega-3, 9.3; 95% difference-in-means CI, -2.2 to 2.4; t(115) = 0.12; P = .90). The groups did not differ on predefined indicators of depression remission (BDI-II < or = 8: placebo, 27.4% vs omega-3, 28.3%; odds ratio [OR], 0.96; 95% CI, 0.43-2.15; t(113) = -0.11; P = .91) or response (> 50% reduction in BDI-II from baseline: placebo, 49.0% vs omega-3, 47.7%; OR, 1.06; 95% CI, 0.51-2.19; t(112) = 0.15; P = .88). CONCLUSIONS: Treatment of patients with CHD and major depression withsertraline and omega-3 fatty acids did not result in superior depression outcomes at 10 weeks, compared with sertraline and placebo. Whether higher doses of omega-3 or sertraline, a different ratio of EPA to DHA, longer treatment, or omega-3 monotherapy can improve depression in patients with CHD remains to be determined. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116857.
RCT Entities:
CONTEXT: Studies of depressed psychiatricpatients have shown that antidepressant efficacy can be increased by augmentation with omega-3 fatty acids. OBJECTIVE: To determine whether omega-3 improves the response to sertraline in patients with major depression and coronary heart disease (CHD). DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial. Between May 2005 and December 2008, 122 patients in St Louis, Missouri, with major depression and CHD were randomized. INTERVENTIONS: After a 2-week run-in period, all patients were given 50 mg/d of sertraline and randomized in double-blind fashion to receive 2 g/d of omega-3 acid ethyl esters (930 mg of eicosapentaenoic acid [EPA] and 750 mg of docosahexaenoic acid [DHA]) (n=62) or to corn oil placebo capsules (n=60) for 10 weeks. MAIN OUTCOME MEASURES: Scores on the Beck Depression Inventory (BDI-II) and the Hamilton Rating Scale for Depression (HAM-D). RESULTS: Adherence to the medication regimen was 97% or more in both groups for both medications. There were no differences in weekly BDI-II scores (treatment x time interaction = 0.02; 95% confidence interval [CI], -0.33 to 0.36; t(112) = 0.11; P = .91), pre-post BDI-II scores (placebo, 14.8 vs omega-3, 16.1; 95% difference-in-means CI, -4.5 to 2.0; t(116) = -0.77; P = .44), or HAM-D scores (placebo, 9.4 vs omega-3, 9.3; 95% difference-in-means CI, -2.2 to 2.4; t(115) = 0.12; P = .90). The groups did not differ on predefined indicators of depression remission (BDI-II < or = 8: placebo, 27.4% vs omega-3, 28.3%; odds ratio [OR], 0.96; 95% CI, 0.43-2.15; t(113) = -0.11; P = .91) or response (> 50% reduction in BDI-II from baseline: placebo, 49.0% vs omega-3, 47.7%; OR, 1.06; 95% CI, 0.51-2.19; t(112) = 0.15; P = .88). CONCLUSIONS: Treatment of patients with CHD and major depression with sertraline and omega-3 fatty acids did not result in superior depression outcomes at 10 weeks, compared with sertraline and placebo. Whether higher doses of omega-3 or sertraline, a different ratio of EPA to DHA, longer treatment, or omega-3 monotherapy can improve depression in patients with CHD remains to be determined. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116857.
Authors: Lee Hooper; Rachel L Thompson; Roger A Harrison; Carolyn D Summerbell; Andy R Ness; Helen J Moore; Helen V Worthington; Paul N Durrington; Julian P T Higgins; Nigel E Capps; Rudolph A Riemersma; Shah B J Ebrahim; George Davey Smith Journal: BMJ Date: 2006-03-24
Authors: Karen M Silvers; Cheryl C Woolley; Frances C Hamilton; Peter M Watts; Rosemary A Watson Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2005-03 Impact factor: 4.006
Authors: Hester M Den Ruijter; Géza Berecki; Tobias Opthof; Arie O Verkerk; Peter L Zock; Ruben Coronel Journal: Cardiovasc Res Date: 2006-06-16 Impact factor: 10.787
Authors: Joost P van Melle; Peter de Jonge; Titia A Spijkerman; Jan G P Tijssen; Johan Ormel; Dirk J van Veldhuisen; Rob H S van den Brink; Maarten P van den Berg Journal: Psychosom Med Date: 2004 Nov-Dec Impact factor: 4.312
Authors: Katherine M Appleton; Robert C Hayward; David Gunnell; Tim J Peters; Peter J Rogers; David Kessler; Andrew R Ness Journal: Am J Clin Nutr Date: 2006-12 Impact factor: 7.045
Authors: Gordon B Parker; Gabriella A Heruc; Therese M Hilton; Amanda Olley; Heather Brotchie; Dusan Hadzi-Pavlovic; Cheryl Friend; Warren F Walsh; Roland Stocker Journal: Psychiatry Res Date: 2006-02-24 Impact factor: 3.222
Authors: Kenneth E Freedland; Robert M Carney; Junichiro Hayano; Brian C Steinmeyer; Rebecca L Reese; Annelieke M Roest Journal: J Psychosom Res Date: 2012-01-28 Impact factor: 3.006
Authors: Kiki P van der Burg; Lachlan Cribb; Chee H Ng; Joseph Firth; Diana Karmacoska; David Mischoulon; Gerard J Byrne; Chad Bousman; Con Stough; Jenifer Murphy; Georgina Oliver; Michael Berk; Jerome Sarris Journal: Eur J Nutr Date: 2019-09-25 Impact factor: 5.614